



The Heart of Great Medicine

Antimicrobial Stewardship Education for Hospitalists

Marsha Crader, PharmD, FASHP

Associate Professor of Pharmacy
Practice

UAMS College of Pharmacy

Co-leader, Antimicrobial Stewardship
Program

St. Bernards Medical Center




Conflicts of Interest

A red crosshair graphic consisting of a vertical line and a diagonal line intersecting.

Marsha Crader, PharmD has no relevant financial relationships with commercial interests to disclose.

Learning Objectives

- 
- A red crosshair graphic consisting of a vertical line and a diagonal line intersecting.
- 1) Describe how to approach hospitalist education regarding antimicrobial stewardship
 - 2) Discuss potential barriers and obstacles to hospitalist engagement with antimicrobial stewardship
 - 3) Summarize common infectious diseases myths in hospital medicine



Hospitalist Education: How to Reach Hospitalists

Hospitalist Education Basics

- **What?**

- Location of local resources
 - Antibigrams, order sets, sepsis requirements for CMS core measures
- Current stewardship focus
 - Joint Commission requirements, hospital goals/initiatives, identified areas for improvement, clinical pearls

- **When?**

- Repeat information through various avenues over multiple years

- **Where?**

- Meet them where they are at – knowledge and physical location
 - Medical staff meetings, CMEs, “handshake” stewardship, competency requirements, provider-specific newsletters, physician lounge bulletin board, etc.

Hospitalist Education Basics

- **How?**

- Communication, communication, communication
 - Repeat a few key points
 - Explain the “why,” “when,” and “how” of making prescribing changes...utilize case examples
 - Share ongoing goal progress...goals and progress need to be visible and audible
 - Peer comparison...generate light, not heat, with data
 - Consider generational and personality differences in communication
- Change the culture and expectation
 - Have a shared vision with prescribers...committee involvement
 - Find out what prescribers want and need to know/understand
 - Utilize interprofessional rounding and peer champions to expand efforts
 - Make the right thing easy to try and to do...hardwire what you can
- Be a physician partner
 - Do not just state the problem and how to fix it, but be a part of the solution

The “Why,” “When,” and “How” of Explaining Prescribing Changes



Why?

- Does antibiotic resistance data or antibiotic usage data drive more prescribing changes?
 - National antibiotic resistance data is good, but local data is better
 - Hospital/Joint Commission-required initiatives/goals

When?

- Which common scenarios provide an opportunity to change prescribing practices?

How?

- What are ways that the hospital is going to support improvements beyond educating prescribers?

Decrease Anti-Pseudomonal Antibiotics

“Why, When, How” Example

Why

- Declining susceptibilities to anti-Pseudomonal antibiotics
 - Piperacillin/tazobactam (2018: x% and 2021: x%)
 - Cefepime (2018: x% and 2021: x%)
 - Meropenem (2018: x% and 2021: x%)

When

- Avoid anti-Pseudomonal agents empirically when unnecessary
 - Diabetic foot infection without history of *Pseudomonas* within previous 6 months or water “soaked” foot
 - Community-acquired, mild-to-moderate severity biliary and extra-biliary infections without the following: sepsis, ≥ 70 years, or immunocompromised
- Avoid collection of urine specimens from patients without signs and symptoms of UTI unless pregnant or undergoing urinary procedure
- De-escalate anti-Pseudomonal agents quickly when possible
 - If preliminary culture from MALDI-TOF NOT identified as *Pseudomonas*
 - If ESBL(+) UTI and susceptible to oral options
- Utilize appropriate durations of therapy

How

- Education to providers and pharmacists
- Maximization of clinical surveillance software
- Order set and microbiology PCR updates



Hospitalist Engagement: Key Strategies and Potential Barriers to Overcome

Engaging Hospitalists in Antimicrobial Stewardship: Lessons From a Multihospital Collaborative



- **Participants**

- 1 community non-teaching hospital, 2 community teaching hospitals, and 2 academic medication centers in a collaborative with CDC and IHI which began with a kick-off in 2012

- **Key Strategies for Engagement**

- 1) Improved documentation/visibility at points of care
 - Making antimicrobial indication, day of therapy, and anticipated durations transparent in the medical record
- 2) Improved guideline clarity and accessibility
 - Enhancing availability of guidelines for frequently encountered infections and clarifying key recommendations such as duration of therapy
- 3) 72-hour time-out: collaborating with clinical pharmacists to assess 3 questions
 - 1) Does the condition require antimicrobials?
 - 2) Can the antimicrobial regimen be tailored based on culture data?
 - 3) What is the anticipated treatment duration?

Engaging Hospitalists in Antimicrobial Stewardship: Lessons From a Multihospital Collaborative



• **Barriers to documentation and optimization of therapy**

1) Schedule and practice variability

- Structure of antimicrobial documentation
- “Prescribing etiquette”
- Competing schedule demands

2) Skepticism of antimicrobial stewardship importance

- Perception that stewardship practices are time consuming
- Competing quality improvement initiatives
- Unclear leadership “buy-in”

3) Focusing too broadly – large initial interventions/unrealistic expectations

Engaging Hospitalists in Antimicrobial Stewardship: Lessons From a Multihospital Collaborative



• **Facilitators to documentation and optimization of therapy**

1) Engage hospitalists

- Determine core group of stewardship “champions”
- Speak one-on-one to colleagues
- Establish leadership “buy-in”
- Encourage multidisciplinary efforts

2) Collect real time data and feedback

- Give feedback often
- Recognize and reward high performers

3) Limit scope

- Start with “low-hanging” fruit and easy integration into hospitalist workflow



Hospitalist Education: Common Antimicrobial Stewardship Topics

Hospitalist Learning Objective Ideas



General Infectious Diseases Topics

- 1) Summarize micro-organism susceptibility patterns from the local antibiogram(s)
- 2) Describe appropriate antibiotic options for common infections based on national guidelines and local antibiogram data
 - Sepsis
 - Skin and soft tissue infections & diabetic foot infections
 - Community-acquired pneumonia
 - Urinary tract infections/asymptomatic bacteriuria
 - *C. difficile*
- 3) Discuss when culture results could be colonization or contamination
- 4) Determine when certain beta-lactam antibiotics may be an option in patients with a penicillin allergy
- 5) Discuss evidence-based durations of antimicrobial therapy

Choosing Empiric Therapy Wisely

- 1) Determine if meet sepsis criteria for CMS core measures
- 2) Assess if likely to have viral instead of bacterial infection
- 3) Order appropriate culture specimens and determine colonization, contamination, or infection
- 4) Review recent previous culture and susceptibility results
- 5) Utilize order sets/antibiogram
- 6) Collect true antibiotic allergy information

Hospital and/or Joint Commission Antimicrobial Stewardship Goals

1) General Antibiotic Usage

- How to decrease inappropriate anti-Pseudomonal usage
- How to decrease inappropriate carbapenem usage
- How to decrease inappropriate MRSA antibiotic usage

2) Appropriate Antibiotic Therapy Selection and Duration of Therapy (for Joint Commission)

- Optimizing guideline and antibiogram-driven antibiotic selection and duration for common infections
- Decreasing inappropriate treatment of asymptomatic bacteriuria
- Improving surgical prophylaxis antibiotic selection and timing of antibiotic administration/duration

Top Myths of Diagnosis and Management of Infectious Diseases in Hospital Medicine

- #1** Antibiotics do no harm
- #2** Antibiotic durations of 7, 14, 21 days are typically necessary
- #3** If one drug is good, 2 (or more) must be better
- #4** PO antibiotics are not as good as IV antibiotics in hospitalized patients
- #5** Bacteria in the urine signifies a UTI and should be treated & cloudy or smelly urine indicates UTI

Top Myths of Diagnosis and Management of Infectious Diseases in Hospital Medicine

#6

History of a penicillin allergy means the patient can never receive a beta-lactam antibiotic

#7

Antibiotics for surgical prophylaxis should typically be continued for at least 24 hours

#8

Antibiotics are necessary if drains are in place

#9

Nitrofurantoin can be used for UTIs only if CrCl > 60 mL/min

#10

Fluoroquinolones remain an excellent 1st-line option for most common infections



Hospitalist Education With and Without Prospective Audit with Feedback: Literature Examples

Impact of Hospitalist-led Interdisciplinary Antimicrobial Stewardship (AS) Interventions at an Academic Medical Center



- **Design**

- 3-arm pre-post study comparing September through December data in 2015 and 2016

- **Setting**

- 3 adult internal medicine teaching services at urban academic hospital

- **Methods**

- **Education bundle** (Ed-only)
- **Educational bundle** + AS rounds bi-weekly with ID-trained pharmacist (Ed+IDPharmDx2)
- **Educational bundle** + IM-trained pharmacist embedded in daily attending rounds Monday – Friday (Ed+IMPharmDx5)

Impact of Hospitalist-led Interdisciplinary Antimicrobial Stewardship Interventions at an Academic Medical Center



• Results

- Total antibiotic usage decreased by
 - Ed-only: 16.8% ($p < 0.001$), Ed+IDPharmDx2: 6.8% ($p = 0.08$), Ed+IMPharmDx5: 33% ($p < 0.001$)
- Broad-spectrum antibiotic use decreased by
 - Ed-only: 26.2% ($p < 0.001$), Ed+IDPharmDx2: 7.8% ($p = 0.09$), Ed+IMPharmDx5: 32.4% ($p < 0.001$)
- Duration of inpatient antibiotic therapy decreased from
 - Ed+IMPharmDx5: 4 to 3 days ($p = 0.01$)
- Length of stay for patient receiving antibiotics decreased from
 - Ed-only: 9 to 7 days ($p < 0.001$) and Ed+IMPharmDx5: 9 to 6 days ($p < 0.001$)
- 30-day readmissions to same facility, transfer to ICU, and in-hospital mortality
 - No significant change for any arm of the study

Impact of Hospitalist-led Interdisciplinary Antimicrobial Stewardship Interventions at an Academic Medical Center



• **Limitations**

- Ed+IDPharmDx2 arm
 - Pre-intervention attending physicians included ID-trained attendings 50% of the time
 - Post-intervention patients included step-down patients not included in pre-intervention

• **Discussion**

- “Champions” from hospital medicine, IM residency program, and pharmacy
- Educational interventions streamlined into prescriber work flow
- In-person rounds

Evaluation of multifaceted approach to antimicrobial stewardship (AS) education for medical residents



- **Design**

- Retrospective cohort study with 295 patients meeting inclusion criteria

- **Setting**

- Community teaching hospital from July 2016 through June 2017

- **Methods**

- 3 medical teams received **baseline AS education and daily prescribing audit with feedback from clinical pharmacists**
 - Family medicine (FM) resident service, internal medicine (IM) resident service, and hospitalist control group
- **FM resident service also received bi-weekly stewardship-focused rounds with antimicrobial stewardship program (ASP) physician and clinical pharmacist leadership**
- Guideline-concordant prescribing was assessed based on institution's ASP guidelines for pneumonia, cellulitis, and UTIs

Evaluation of multifaceted approach to antimicrobial stewardship (AS) education for medical residents



• Results

- No difference in empiric or definitive antibiotic selection but FM resident service was more likely to prescribe guideline-concordant duration of therapy across all diagnoses
 - Empiric: FM=87.5%, IM=87%, hospitalist=83.8%; $p=0.702$
 - Definitive: FM=92.4%, IM=89.1%, hospitalist=89.9%; $p=0.746$
 - Duration of therapy: FM=74%, IM=56.5%, hospitalist=44.6%; $p<0.001$

• Limitations

- Limited to uncomplicated infections
- High rate of emergency department prescriber guideline-concordance likely influenced empiric therapy selection of study groups



Educational Resources & Tips

Resources and Tips: Allergies and Durations of Therapy



- **Penicillin allergies**

- <https://www.cdc.gov/antibiotic-use/community/pdfs/penicillin-factsheet.pdf>
- Blumenthal KG, et al. *Lancet*. 2019;393(10167): 183-198.
- Khan DA, et al. *J Allergy Clin Immunol*. 2022;150(6):1333-1393.
- Blumenthal KG, et al. *Clin Infect Dis*. 2018;66(3):329-36.
- Vorobeichik L, Weber EA, and Tarshis J. *Anesth Analg*. 2018;127(3):642-649.

- **Duration of therapy**

- Davar K, et.al. *Open Forum Infect Dis*. 2022;10(1): ofac706.
 - Shorter therapy is just as efficacious as longer therapy
 - Cellulitis/wound/abscess: 5-6 days
 - CAP: 3-5 days
 - Complicated UTI/pyelonephritis: 5-7 days
- Teshome BF, et.al. *Pharmacotherapy*. 2019;39(3): 261-270.
 - Increased risk of new resistance for each additional day of any anti-Pseudomonal beta-lactam antibiotic exposure
 - Cefepime and piperacillin-tazobactam: 8% for each additional day
 - Meropenem: 2% for each additional day

Resources and Tips: UTIs – Duration of Therapy



- **Each medication's duration is different**
- **Uncomplicated cystitis**
 - Nitrofurantoin x 5 days (female) and x 7 days (male)
 - Cephalexin **four times daily** x 5 days
 - TMP/SMX x 3 days (female) and x 7 days (male)
 - Fosfomycin x 1 dose
- **Complicated cystitis/pyelonephritis**
 - TMX/SMX x 7 days
 - Ciprofloxacin and Levofloxacin x 5-7 days
 - Beta-lactams x 10-14 days

Resources and Tips: Skin and Soft Tissue Infections



- **Skin and soft tissue infections**
 - Non-purulent → *Streptococcus* unless severe, necrotizing infection
 - Purulent → *Staphylococcus* + incision and drainage

Resources and Tips: Skin and Diabetic Foot Infections



- **Diabetic foot infections**

- Cover for *Staphylococcus* and *Streptococcus*
- Cover for Gram (-) bacilli
 - Recent antibiotic exposure in mild severity
 - All scenarios in moderate or severe severity
 - *Pseudomonas* only a concern if grown from wound within previous few weeks or wound “water soaked”
- Cover for anaerobes with ischemic, necrotic, and gas-forming wounds

Resources and Tips: Community-acquired Pneumonia



- **Community-acquired pneumonia**

- Avoid fluoroquinolones unless necessary (see last slide for MedWatch warnings)

- **Outpatient**

- Without co-morbidities → *Streptococcus pneumoniae*
- With co-morbidities → *Strep pneumoniae*, *H. flu*, *M. cat*, and atypicals
- Is azithromycin a viable option for *Strep pneumo* based on antibiogram?

- **Inpatient**

- All patients → *Strep pneumoniae*, *H. flu*, *M. cat*, and atypicals
- History of MRSA from respiratory specimen within last year → add MRSA
 - Discontinue MRSA coverage if MRSA PCR nasal screen negative
- History of *Pseudomonas* from respiratory specimen within last year → add *Pseudomonas*
- Hospitalization + IV antibiotics + locally validated risk factors → add MRSA and/or *Pseudomonas* in severe CAP empiric therapy

Resources and Tips: Urinary Tract Infections (UTI)



- **Asymptomatic bacteriuria**

- Avoid collecting urine specimens from any patients without signs/symptoms of UTI
 - Continue to collect and treat patients with bacteriuria who are pregnant or undergoing an invasive genitourinary procedure
- Prevalence of bacteriuria in patients with a long-term urinary catheter is 100%
- Avoid assumption that confusion and falls in the elderly are always due to a UTI
 - Could it be a stroke, polypharmacy, dehydration, etc.?

- **Urinary tract infections**

- Positive UA in patients with chronic urinary catheters are not as useful since pyuria and hematuria may be present without UTI
- Review previous culture results for empiric therapy because extended-spectrum beta-lactamases (ESBLs) are on the rise
- Nitrofurantoin and fosfomycin only treat cystitis

Gupta K, et al. *Clin Infect Dis*. 2011;52(5): e103-120.

Tamma PD, et.al. *Clin Infect Dis*. 2023 (in press).

<https://www.idsociety.org/practice-guideline/amr-guidance/#null>

Nicolle LE, et.al. *Clin Infect Dis*. 2019; 68(10): e83-75.

Resources and Tips

Avoid Fluoroquinolones



- “FDA has determined that **fluoroquinolones should be reserved for use in patients who have no other treatment options** for acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections because the **risk of these serious side effects generally outweighs the benefits** in these patients.”
- Multiple MedWatch Warnings identified
 - CNS → peripheral neuropathy (potentially permanent)
 - Heart → arrhythmias, aortic aneurysm
 - Hypoglycemia
 - Tendinitis/tendon rupture
- FYI: local antibiogram susceptibilities may not optimal for empiric usage in many common inpatient and outpatient infections



Questions?

Question #1

Select All That Apply



Antimicrobial stewardship education for hospitalists can be accomplished through which of the following methods?

- ☐ Continuing medical education (CME)
- ☐ Medical/hospitalist staff meetings
- ☐ “Handshake” stewardship
- ☐ Joint Commission competency requirements

Question #2

Multiple Choice



Which of the following is/are potential barrier(s) to hospitalist antimicrobial stewardship engagement?

- A. Inconsistent structure and visibility of antibiotic documentation
- B. Clear hospital leadership support
- C. Limiting scope of antimicrobial stewardship initiatives
- D. All of the above
- E. None of the above

Question #3

Multiple Choice

Which of the following is/are myth(s) regarding infectious diseases?

- A. Bacteria in the urine should always be treated
- B. Patients with penicillin allergies should never receive a beta-lactam antibiotic
- C. Antibiotics do no harm
- D. Antibiotic duration of therapy with at least 7 days is always necessary
- E. All of the above
- F. None of the above